A study of long-term survivors of pediatric Hodgkin lymphoma presented at the 2022 American Society of Hematology Annual Meeting and Exposition shows that they have an increased risk for cognitive impairment and early death when compared with individuals who never had the disease. The results suggest that they may experience accelerated aging and that assessing the biomarker for epigenetic age acceleration could be critical in addressing long-term effects of treatment on survivors of cancer.

You do not currently have access to this content.